WO1999021005A3 - Millepertuis de qualite pharmaceutique - Google Patents

Millepertuis de qualite pharmaceutique Download PDF

Info

Publication number
WO1999021005A3
WO1999021005A3 PCT/US1998/022504 US9822504W WO9921005A3 WO 1999021005 A3 WO1999021005 A3 WO 1999021005A3 US 9822504 W US9822504 W US 9822504W WO 9921005 A3 WO9921005 A3 WO 9921005A3
Authority
WO
WIPO (PCT)
Prior art keywords
wort
john
materials
pharmaceutical grade
present
Prior art date
Application number
PCT/US1998/022504
Other languages
English (en)
Other versions
WO1999021005A2 (fr
Inventor
Tasneem A Khwaja
Elliot P Friedman
Original Assignee
Pharmaprint Inc
Univ Southern California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/956,602 external-priority patent/US6113907A/en
Application filed by Pharmaprint Inc, Univ Southern California filed Critical Pharmaprint Inc
Priority to EP98957355A priority Critical patent/EP1094825A2/fr
Priority to AU13631/99A priority patent/AU1363199A/en
Priority to CA002306818A priority patent/CA2306818A1/fr
Publication of WO1999021005A2 publication Critical patent/WO1999021005A2/fr
Publication of WO1999021005A3 publication Critical patent/WO1999021005A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/67—Piperaceae (Pepper family), e.g. Jamaican pepper or kava
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/84—Valerianaceae (Valerian family), e.g. valerian

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention a trait de manière générale à des matières de ginseng et à des procédés de transformation de ces matières en formes utiles d'un point de vue médicinal et pharmaceutiquement acceptables. Plus particulièrement, l'invention a trait à l'utilisation d'empreintes de composition et d'activité dans le traitement de matières de ginseng pour produire des médicaments qui remplissent les conditions requises pour constituer des compositions de qualité pharmaceutique convenant pour un usage clinique ou vétérinaire en vue de traiter et/ou soulager des maladies, des affections ou des états pathologiques.
PCT/US1998/022504 1997-10-23 1998-10-23 Millepertuis de qualite pharmaceutique WO1999021005A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP98957355A EP1094825A2 (fr) 1997-10-23 1998-10-23 Millepertuis de qualite pharmaceutique
AU13631/99A AU1363199A (en) 1997-10-23 1998-10-23 Pharmaceutical grade st. john's wort
CA002306818A CA2306818A1 (fr) 1997-10-23 1998-10-23 Millepertuis de qualite pharmaceutique

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/956,602 1997-10-23
US08/956,602 US6113907A (en) 1997-04-15 1997-10-23 Pharmaceutical grade St. John's Wort
US15931398A 1998-09-23 1998-09-23
US09/159,313 1998-09-23

Publications (2)

Publication Number Publication Date
WO1999021005A2 WO1999021005A2 (fr) 1999-04-29
WO1999021005A3 true WO1999021005A3 (fr) 2001-02-22

Family

ID=26855832

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/022504 WO1999021005A2 (fr) 1997-10-23 1998-10-23 Millepertuis de qualite pharmaceutique

Country Status (4)

Country Link
EP (1) EP1094825A2 (fr)
AU (1) AU1363199A (fr)
CA (1) CA2306818A1 (fr)
WO (1) WO1999021005A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100407399B1 (ko) * 2000-08-22 2003-11-28 주식회사 뉴로넥스 세로토닌 ｎ-아세틸트란스퍼라제의 활성 억제제
EP1377286A1 (fr) * 2001-02-20 2004-01-07 Randy H. Ziegler Traitement de la schizophrenie
CN111175428B (zh) * 2020-01-07 2022-09-09 江苏省中医院 补肾助孕颗粒指纹图谱的检测方法
CN112697899B (zh) * 2020-12-07 2022-04-12 中国药科大学 一种银杏黄酮醇苷的检测方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH680570A5 (en) * 1990-10-30 1992-09-30 Flint Ag Allergen-free St. Johns wort extract prodn. to prevent skin tumour - by macerating mechanically comminuted St. Johns wort and camomile with a plant oil e.g. wheat germ, thistle, sunflower seed, etc.
WO1997039355A1 (fr) * 1996-04-15 1997-10-23 Pharmaprint, Inc. Medicaments botaniques de qualite pharmaceutique

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH680570A5 (en) * 1990-10-30 1992-09-30 Flint Ag Allergen-free St. Johns wort extract prodn. to prevent skin tumour - by macerating mechanically comminuted St. Johns wort and camomile with a plant oil e.g. wheat germ, thistle, sunflower seed, etc.
WO1997039355A1 (fr) * 1996-04-15 1997-10-23 Pharmaprint, Inc. Medicaments botaniques de qualite pharmaceutique

Also Published As

Publication number Publication date
WO1999021005A2 (fr) 1999-04-29
CA2306818A1 (fr) 1999-04-29
EP1094825A2 (fr) 2001-05-02
AU1363199A (en) 1999-05-10

Similar Documents

Publication Publication Date Title
CA2392879A1 (fr) Derive de pyrrolidine acetamide seul ou combine pour traiter des affections du snc
IL152659A (en) Liquid pharmaceutical compositions comprising a pegylated human erythropoietin protein and a multiple charged inorganic anion, in a pharmaceutically acceptable buffer
WO2001041761A3 (fr) Compositions de valdecoxib
ZA975866B (en) Novel heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases.
MA26536A1 (fr) Association de compositions pharmaceutiques d'atorvastatine et d'agents antihypertensifs, et procede pour leur preparation.
HUP0104867A3 (en) Heterocyclic compounds useful in the treatment of inflammatory diseases, process for their preparation, pharmaceutical compositions comprising thereof and their use
MA26420A1 (fr) Compositions pharmaceutiques mixtes pour le traitement de l'osteoporose, et procede pour leur preparation.
WO1999048482A3 (fr) Smilagenine et anzurogenine d et leur utilisation
AU2509895A (en) Fluoxetine pharmaceutical formulations
WO2001009118A3 (fr) Composes dithiolthione pour le traitement de troubles neurologiques et pour renforcer la memoire
IL112665A (en) 5-Substituted derivatives of mycophenolic acid their preparation and pharmaceutical compositions containing them
IL112667A0 (en) 6-substituted derivatives of mycophenolic acid, their preparation and pharmaceutical compositions containing them
HUP0301167A3 (en) Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders, process for their preparation, pharmaceutical compositions containing them and their use
CA2436540A1 (fr) Composition pharmaceutique a base d'anticholinergiques et de corticosteroides
EP0797999A3 (fr) Formulations de protéine d'obésité
MY118526A (en) Method for improving the pharmacokinetics of tipranavir
AU2001266152A1 (en) Novel substituted nitrocatechols, their use in the treatment of some central andperipheral nervous system disorders and pharmaceutical compositions containing them
WO2001001974A3 (fr) Compositions pharmaceutiques et procedes permettant de traiter l'anxiete, les troubles anxieux et la perte de memoire, par utilisation d'inhibiteurs de naaladase
ZA98960B (en) Pharmaceutical composition for treatment of synaptic dysfunction and related disease disorders
AU3364499A (en) Method for delaying the onset of alzheimer's disease and for treating or delaying the onset of other amyloidosis-related diseases/disorders
WO1999020291A3 (fr) Gingko biloba de qualite pharmaceutique
HK1079688A1 (en) Statin product for enhancing cognitive maintenance
HUP0401325A3 (en) Isoxazolopyridinones useful in the treatment of parkinson's disease, process for their preparation and pharmaceutical compositions containing the compounds
CA2217513A1 (fr) Agents pharmaceutiques pour le traitement de la maladie d'alzheimer
MXPA02000680A (es) Polipeptidos vgf y metodos para tratar desordenes relacionados con vgf.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2306818

Country of ref document: CA

Ref country code: CA

Ref document number: 2306818

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1998957355

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 13631/99

Country of ref document: AU

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWP Wipo information: published in national office

Ref document number: 1998957355

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1998957355

Country of ref document: EP